<DOC>
	<DOCNO>NCT01860625</DOCNO>
	<brief_summary>Study Safety , tolerability pharmacokinetics single dose donepezil patch healthy male subject .</brief_summary>
	<brief_title>A Phase I Clinical , Dose Escalation Study Safety , Tolerability Pharmacokinetics Donepezil Patch Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>BMI : 20 ㎏/㎡ , less 26 ㎏/㎡ Systolic blood pressure : 90 , less 140 ( mmHg ) Diastolic blood pressure : 60 , less 100 ( mmHg ) Evidence clinically significant , severe , active , unstable gastrointestinal , renal , hepatic , respiratory , hematological , endocrine , cardiovascular system disease . A history skin disease skin graft Hypersensitivity donepezil piperidine derivative excipients . A known suspected history drug alcohol dependency abuse Patients participate another clinical study within 60 day . Whole blood within 60 day , apheresis within 30 day , transfusion within 30 day Heavy caffeine intake ( 5 units/day ) Heavy alcohol intake ( 21 units/week ) Heavy smoker ( 10 cigarette/day ) Abnormal clinical laboratory value judge clinically significant investigator . Any condition would make patient caregiver , opinion investigator , unsuitable study .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>